橡DI月報200.PDF

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "橡DI月報200.PDF"

Transcription

1 DI WHIWomen s Health Initiative 15 8 Million women study HRT : : : : :2.31 HRT 1 :1.81 HRT :1.31 HRT 65 :2.05 CKCPK

2 5mg mg HIV HIV HIV CD4 500/mm 3 1 1,250mg mg 1 3 HIV cap 50mg 1 200mg ph mg 5mL

3 BUN/ Japan Coma Scale 100 DIC BUN ASTGOTALTGPT LDH CKCPK BUN/ Japan Coma Scale 100

4 DIC %5 /1, %12 /852 (1) (2) cap cap Cmax6.6 AUC mg/kg 20mg/kg 1mg/kg

5 cap 35mg/m mg/ m Lyell cap cap 2hr 1hr 2hr Child-Pugh 1 600mg 1 3 P4503A4CYP3A4 CYP3A4 cap 2hr 1hr 2hr 2 600mg8hr 800mg8hr 300mg mg1 1 2 AUC 800mg8hr 34% 33% AUC 300mg % 55% HIV 2 600mg8hr 800mg8hr 200mg1 1 AUC Cmax 31%16% HIV CYP3A4 BUN

6 cap B C Cmax AUC 32% 38% HIV 1,200mg/12 600mg/ Cmax33%AUC24% Cmin43% CYP3A

7 1.5L 2,162.0 UV mg 10mg Oxycodone HCl 20mg 40mg , mg 10mg 20mg 40mg Cap LPV 133.3mg RTV 33.3mg Lopinavir(LPV)Ritonavir(RTV) HIV LPV RTV mg 90.0 Azelnidipine PF 2%/5mL (5mL) Cromoglicate Na mg Loratadine H mg Telithromycin mg Prulifloxacin ( )

8 40mg Sotalol HCl Ca HD 98.6g /100g g Barium sulfate X P N 300U 02,462.0 /3mL/ 10R 2, R 2, R 2, R50R ,500U /V 500mg /100mL / 96,872.0 Human Antithrombin AT 1,500U/ P(500)3111,180 (1,500)1 96, ,112.0 Pazufloxacin mesilate mg 6.4 Pyridoxal phosphate B V mg /0.6mL 13,732.8 Hyaluronate Na mg 35.6 Sevelamer HCl CaAl Ca PF 2%/5mL 1,262.5 (5mL) Carteolol HCl 1 2%

9 200mg /2.5mL/V 400mg /5mL/V MS 20,000U /0.5g 90g/V 180g/V 1, , mL/V 2,818.0 Fosfluconazole Pronase ,634.0 Peginterferon--2a 30, a C IFN IFN600 U B B -HB mL 10,794.0 Meglumine gadoterate / MRI Gd 14, , mg 02,503.3 Folinate CaLV QOL mg Pitavastatin Ca HMG-CoA LDL CYP PF 0.1%/5mL (5mL) Betamethasone Na Phosphate

10 20mg/ 1,171.0 Sumatriptan 5-HT 1B/1D ,719.5 Desmopressin acetate 500g 10 /5mL/ Cap 10mg Ciclosporin mg/mL 1,371.1 Ciclosporin (1mL) mg/ Tacrolimus hydrate (1 ) mg/A 2,377.0 Nicardipine HCl 50mg 2A 10mg 5A 25mg24, mg55,

11 6,000U 11,625.0 Epoetin / 6,000U/V % g 10,000U / 960 U /V Colestimide 70% Thrombin 5,000U/V ,683.0 Interferon-1b Cap 250mg 10.6 Mefenamic acid Cap

12 25g 6,000U/V 6,000U/ 70% 83% 5g/50mL/ 200mg/100mL/V 50mg/5mL/V 5,000U/V 10,000U/ T 10%1,000mL/ P 100g HD 56mg/5mL/A 960 U/V CMV 2.5g/V 10R 300U/3mL/V 10R (300U/3mL/) 50R 300U/3mL/V 50R (300U/3mL/) 6mg Cap Metha

13

14

15 P.15 P.21 P.21

16 P.26 P.30 P.64

17 P.68

18 P.79 P.123 P.98

19 P.123

20 P.135 P.159 P.151

21 P.171 P.188

22 P.251 P.253

23 P.254 P.273

24 P.274 P.330 P.329

25 P.333 P.336 P.360

26 P.378 P.380

27 P.383

28 P.406 P.386 P.396

29 P.409

30

31 117

32

橡DI月報178.PDF

橡DI月報178.PDF 2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h htmL)

No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h htmL) Drug Information News No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h0925-1.htmL) 2 No.192 HP DI [ ] 1. -1a - 50 100 300 2. 7501500 3000750 1500 3000 60009000 12000240006000 9000 12000 24000

More information

橡サプリメント.PDF

橡サプリメント.PDF Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004

More information

untitled

untitled 1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT

More information

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) 2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

More information

untitled

untitled - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -

More information

I

I I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

More information

ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G

More information

1) 1) 1 R 2 3 4 5 6 3) 4) 5) Punch 7 10g/mL(63.6mol/L) 20mg/kg 78 5 23 Cmax 250mg 3.9g/ml 500mg 6.0g/ml1000mg 8g/ml2000mg 15g/ml 33.4 110-116mL/min 1,8) 8 95 9 10 ( ) 11 desa 12 13 12) 2.5 5 19 Rec assayames

More information

アクテムラインタビューフォーム

アクテムラインタビューフォーム 2009 2 6 876399 IF 1998 9 FAX 80mg 1 4mL 80mg 200mg 1 10mL200mg 400mg 1 20mL400mg JAN TocilizumabGenetical RecombinationJAN 200mg 80400mg 2007 9 10 2008 4 16 2007 12 21 2008 6 13 2005 6 13 2008 6 13 2009

More information

27 2 17 学 説 試 験 問 題 (B) 80 2 81 81 のうち を 横 線 で 81 とマークすれば 良 い HB 良 い 例 悪 い 例 1 Na + 2 K 3 kg mg/kg AUC. g/hr/m. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg. 4 Na + -K + -ATPase 5 a b c d e a, b a, e b,

More information

Taro9-医薬品目次2012-1.PDF

Taro9-医薬品目次2012-1.PDF 5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20

More information

まえがき

まえがき JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------

More information

20-121

20-121 20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150

More information

パソコン接続マニュアル P-01F 日本語

パソコン接続マニュアル P-01F 日本語 P-01F 1 2 3 4 5 1 2 +m1111 1 2 3 4 5 6 6 1 1 111 2 1 3 1 1 1 2 1 7 3 8 1 2 1 111 3 4 5 9 1 m111 m1111 c 2 3 4 5 10 1 1 111 2 1 3 1 1 1 2 1 3 1 m111 m1111 2 3 1 11 12 1 2 3 1 2 3 13 1 2 3 4 5 14 6 7 8 9

More information

コンタクト.PDF

コンタクト.PDF Vol.12,No.4,2003 Sep.2003 Vol.12 No.4 CL CL HCL BAK CL 5 1/10 CL 5 CL 80% CL CL 6 2 CL CL 3 67 Vol.10,No1,2001 ph 7.5 3 2 9mm 90% 7 2 68 1 12ml 3 3 3 Vol.10,No.1,2001 69 IgA 1 0.16 2L CL Vol.10,No1,2001

More information

DFC Dialysis Facility Compare g/dl UPR65% UPR BUN BUN/ BUN NEJM, March10,2005 Anemia of C

DFC  Dialysis Facility Compare g/dl UPR65% UPR BUN BUN/ BUN NEJM, March10,2005 Anemia of C HemodialysisReview Article: Medical ProgressNEJM, Nov.4, 2010 H23.1 80 20 1 Dialyser NEJM 1 6.6 15.6 21.7 1 21.7 AV fistula 3 1 4 1 1980 Kt/V urea Vml t 1.4 8 12 DFC: Dialysis Facility Compare DFC http://www.cms.gov/dialysisfacilitycompare/

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

近畿中国四国農業研究センター研究報告 第7号

近畿中国四国農業研究センター研究報告 第7号 230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15

More information

肝臓病教室201207v2配布用.pptx

肝臓病教室201207v2配布用.pptx 24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

ケイセントラ_製品情報概要_H1-4_収載_新発売

ケイセントラ_製品情報概要_H1-4_収載_新発売 DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1

More information

1 2

1 2 1 2 4 3 5 6 8 7 9 10 12 11 0120-889-376 r 14 13 16 15 0120-0889-24 17 18 19 0120-8740-16 20 22 21 24 23 26 25 28 27 30 29 32 31 34 33 36 35 38 37 40 39 42 41 44 43 46 45 48 47 50 49 52 51 54 53 56 55 58

More information

3 5 6 7 7 8 9 5 7 9 4 5 6 6 7 8 8 8 9 9 3 3 3 3 8 46 4 49 57 43 65 6 7 7 948 97 974 98 99 993 996 998 999 999 4 749 7 77 44 77 55 3 36 5 5 4 48 7 a s d f g h a s d f g h a s d f g h a s d f g h j 83 83

More information

M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1

More information

取扱説明書 [F-12C]

取扱説明書 [F-12C] F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X

More information

無印良品のスキンケア

無印良品のスキンケア 2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240

More information

31, 21% 24, 17% 8, 5% 23, 16% 24, 16% 91, 62% 19, 13% 39, 27% 33, 23% 73 48 57 51 31 1 9 13.0% 7.4% 5.3% 12.5% 17.1% 13.2% 17.9% 4.5% 36.4% 56.5% 40.7% 36.8% 50.0% 67.1% 56.3% 65.8% 75.0% 26.0% 37.0%

More information

% 32.3 DI DI

% 32.3 DI DI 2011 7 9 28.1 41.4 30.5 35.8 31.9% 32.3 DI 18.2 2.4 8.1 3.5 DI 9.4 32.2 0.0 25.9 2008 1 3 2 3 34.8 65.2 46.753.8 1 2 8.82.9 43.1 10 3 DI 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

More information

Taro10-mizushima01.PDF

Taro10-mizushima01.PDF - 1 - ATAGO N- % % g % g % g % g % g % g Brix% g g ml ml mgm / l ml mg mol/l mol/l mol/l ph NaSO mol/ l ml / g mg mg ml mol/l ml ml L- L- FIBE-MINI FIBE-MINI % % FIBE-MINI % g % g % g % C mg mg mg

More information

untitled

untitled Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb

More information

05[和]_061-078[島田](責)山.indd

05[和]_061-078[島田](責)山.indd 1858 1919 1. 1877 10 Studies in English and American Literature, No. 45, March 2010 2010 by the Engish Literary Society of Japan Women s University 62 1 1890 23 1 2 2 3 3 1891 1 1892 6 1892 9 1893 12 4

More information

平成25年度調理師試験問題

平成25年度調理師試験問題 25 15 60 HB 2 1 1 2 36 1961 46 1971 56 1981 3 1991 3 4-1 - 5 6 7 8 6 2 12 31 1 15 1 15 4 15 4 15-2 - 9-3 - 10 11 12 13 3-4 - 14 腿 15 16 WHO 22 2010 17 18 1-5 - 19 1 g 4 kcal 4 kcal 9 kcal 9 kcal 20 21

More information

2009 2 1 2012 Vol.37 No.1 Contents 4 11 MEDICAL FRIEND CO.,LTD.2012 16 24 32 38 43 1 3 Part SERIES 54 100 BOOK 80 58 NEWS 52 Scope 2 64 41 68 ICT 72 42 63 63 88 Information 82 お お し ま と し こ 資 料 1 3 1996

More information

IF 1 63 2 IF IF 10 9 3 IF 10 20 9 IF 2 IF IF IF IF IF A4 9 IF IF 2 IF IF IFIF IF

IF 1 63 2 IF IF 10 9 3 IF 10 20 9 IF 2 IF IF IF IF IF A4 9 IF IF 2 IF IF IFIF IF 2011 年 6 月 改 訂 ( 改 訂 第 2 版 ) 日 本 標 準 商 品 分 類 番 号 872171 医 薬 品 インタビューフォーム IF 2008 Ca ++ 拮 抗 性 不 整 脈 虚 血 性 心 疾 患 治 療 剤 日 本 薬 局 方 ベラパミル 塩 酸 塩 錠 剤 形 製 剤 の 規 制 区 分 規 格 含 量 1 40mg 一 般 名 製 造 販 売 承 認 年 月 日 薬 価

More information

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx 24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)

More information

1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C).91 177 2 Thiamine (B1) 1.1 265 5 Nicotinic Acid (B3) 1.27 124 15 Pyridoxal (

1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C).91 177 2 Thiamine (B1) 1.1 265 5 Nicotinic Acid (B3) 1.27 124 15 Pyridoxal ( ACQUITY UPLC H-Class ACQUITY QDa Mark E. Benvenuti, Dimple Shah, and Jennifer A. Burgess Waters Corporation, Milford, MA, USA MS ACQUITY QDa UPLC HPLC UV ACQUITY QDa LC EC 1925/26 CFR 21 HPLC 1 LC-MS ACQUITY

More information

untitled

untitled 2007 12 1 871146 IF 1998 9 350mg 250mg 100mg 10mg 10mg Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride 2007 8 31 2007 12 21 1955 2 FAX TEL FAX IF 2007 12 6 IF 1

More information

untitled

untitled NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10

More information

17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2

17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2 1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)

More information

1 2 http://www.japan-shop.jp/ 3 4 http://www.japan-shop.jp/ 5 6 http://www.japan-shop.jp/ 7 2,930mm 2,700 mm 2,950mm 2,930mm 2,950mm 2,700mm 2,930mm 2,950mm 2,700mm 8 http://www.japan-shop.jp/ 9 10 http://www.japan-shop.jp/

More information

第18回海岸シンポジウム報告書

第18回海岸シンポジウム報告書 2011.6.25 2011.6.26 L1 2011.6.27 L2 2011.7.6 2011.12.7 2011.10-12 2011.9-10 2012.3.9 23 2012.4, 2013.8.30 2012.6.13 2013.9 2011.7-2011.12-2012.4 2011.12.27 2013.9 1m30 1 2 3 4 5 6 m 5.0m 2.0m -5.0m 1.0m

More information

1 911 34/ 22 1012 2/ 20 69 3/ 22 69 1/ 22 69 3/ 22 69 1/ 22 68 3/ 22 68 1/ 3 8 D 0.0900.129mm 0.1300.179mm 0.1800.199mm 0.1000.139mm 0.1400.409mm 0.4101.199mm 0.0900.139mm 0.1400.269mm 0.2700.289mm

More information

液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D

液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D 1 2 3 4 5 6 7 1 2 3 4 5 6 7 2 2 2 1 1 2 9 10 11 12 13 14 15 16 17 1 8 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 9 11 12 13 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 11 12

More information

000-.\..

000-.\.. 1 1 1 2 3 4 5 6 7 8 9 e e 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 10mm 150mm 60mm 25mm 40mm 30mm 25 26 27 1 28 29 30 31 32 e e e e e e 33 e 34 35 35 e e e e 36 37 38 38 e e 39 e 1 40 e 41 e 42 43

More information

1 1 36 223 42 14 92 4 3 2 1 4 3 4 3429 13536 5 6 7 8 9 2.4m/ (M) (M) (M) (M) (M) 6.67.3 6.57.2 6.97.6 7.27.8 8.4 5 6 5 6 5 5 74 1,239 0 30 21 ( ) 1,639 3,898 0 1,084 887 2 5 0 2 2 4 22 1 3 1 ( :) 426 1500

More information

1 C 2 C 3 C 4 C 1 C 2 C 3 C

1 C 2 C 3 C 4 C 1 C 2 C 3 C 1 e N >. C 40 41 2 >. C 3 >.. C 26 >.. C .mm 4 C 106 e A 107 1 C 2 C 3 C 4 C 1 C 2 C 3 C 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124

More information

21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4

21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4 462015 Nagoya community school for health Think health scientifically : the life style and the health condition of seminar participants Hisae USAMI 21 36 67 1/3 21 21 21 1 23 6 68.2 91 43 70 42.56037.5

More information

!!! 10 1 110 88 7 9 91 79 81 82 87 6 5 90 83 75 77 12 80 8 11 89 84 76 78 85 86 4 2 32 64 10 44 13 17 94 34 33 107 96 14 105 16 97 99 100 106 103 98 63 at 29, 66 at 58 12 16 17 25 56

More information

untitled

untitled 1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,

More information

評価結果報告書の概要版(平成20年度)

評価結果報告書の概要版(平成20年度) 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76

More information

....

.... 2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin

More information